1 October 2019 in Acta Biomaterialia
1 March 2021 in Journal of Korean Neurosurgical Society
Shunt infection is a common complication while treating hydrocephalus. The antibiotic-impregnated shunt catheter (AISC) was designed to reduce shunt infection rate. A meta-analysis was conducted to study the effectiveness of AISCs in reduction of shunt infection in terms of age, follow-up time and high-risk patient population. This study reviewed literature from three databases including PubMed, EMBASE, and Cochrane Library (from 2000 to March 2019). Clinical studies from controlled trials for shunt operation were included in this analysis. A subgroup analysis was performed based on the patient's age, follow-up time and high-risk population. The fixed effect in RevMan 5.3 software (Cochrane Collaboration) was used for this meta-analysis. This study included 19 controlled clinical trials including 10105 operations. The analysis demonstrated that AISC could reduce the infection rate in shunt surgery compared to standard shunt catheter (non-AISC) from 8.13% to 4.09% (odds ratio [OR], 0.48; 95% confidence interval [CI], 0.40-0.58; p=0.01; I2=46%). Subgroup analysis of different age groups showed that AISC had significant antimicrobial effects in all three groups (adult, infant, and adolescent). Follow-up time analysis showed that AISC was effective in preventing early shunt infections (within 6 months after implant). AISC is more effective in high-risk population (OR, 0.24; 95% CI, 0.14-0.40; p=0.60; I2=0%) than in general patient population. The results of meta-analysis indicated that AISC is an effective method for reducing shunt infection. We recommend that AISC should be considered for use in infants and high-risk groups. For adult patients, the choice for AISC could be determined based on the treatment cost.
26 March 2025 in Biomedical Materials
Intervention without implantation has become a requirement for developing percutaneous coronary intervention for coronary heart disease. In this paper, the recent advances of three representative types of bioresorbable metal coronary drug-eluting stents (DESs) are reviewed, and the material composition, structural design, mechanical properties and degradability of iron-based, magnesium-based and zinc-based bioresorbable metal coronary DES are analyzed. The methods of regulating the radial strength and degradation rate of the coronary stents are summarized, and the in vivo/in vitro performance evaluation methods and ideal testing systems of the bioresorbable metal coronary DES are analyzed. Advances made in bioresorbable metal coronary DES, the existing shortcomings and optimization methods are proposed, and the future development direction is prospected.